Phase 2 Clinical Study into Empasiprubart for Multifocal Motor Neuropathy
Time: 11:30 am
day: Conference Day Two
Details:
- Targeting C2 to inhibit function and downstream complement activation
- Reducing tissue inflammation and adaptive immune responses in autoimmune indications
- Clinical update on Empasiprubart for MMN
